GRPD: Officer-social worker 'co-response' team reduces ER visits, jail bookings
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
3 minutes ago
- Washington Post
Hall of Fame second baseman Ryne Sandberg has died after battling cancer
CHICAGO — Ryne Sandberg, a Hall of Fame second baseman who became one of baseball's best all-around players while starring for the Chicago Cubs, has died. He was 65. Sandberg was surrounded by his family when he died at his home on Monday, according to the team. Sandberg announced in January 2024 that he had been diagnosed with metastatic prostate cancer. He had chemotherapy and radiation treatments, and then said in August 2024 that he was cancer-free.
Associated Press
33 minutes ago
- Associated Press
Xtant Medical Partners With B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market Opportunity
The Partnership Will Deliver Centralized, Investor-focused Content to Help Retail and Institutional Audiences Gain Insight Into Xtant's Orthobiologics Platform and Long-term Value Proposition NEW YORK, NY - July 28, 2025 ( NEWMEDIAWIRE ) - B2i Digital is pleased to announce that Xtant Medical Holdings (NYSE American: XTNT) has been named a B2i Digital Featured Company. Xtant is a global medical technology company that develops, manufactures, and markets a full-service portfolio of regenerative medicine products and related medical devices for orthopedic and neurosurgical specialists. The company's vertically integrated model allows it to offer a full-service product line that includes bone-healing grafts, growth-factor biologics, cellular allografts, synthetics, and amnion products. This integration, combined with a robust R&D pipeline that includes multiple next-generation biologics scheduled for launch through 2025, underpins its strategy for driving margin improvement and long-term, sustainable growth. 'We are pleased to showcase Xtant Medical to our investor community at this pivotal time in the company's expansion and evolution,' said David Shapiro, CEO of B2i Digital. 'With its vertically integrated platform covering all five major orthobiologic categories and a clear trajectory of revenue growth, the company presents a compelling story for investors interested in the medical technology sector. Xtant's established distribution network and robust product pipeline position it well within a multi-billion-dollar market.' Sean Browne, CEO of Xtant Medical, commented, 'Our partnership with B2i Digital will help us share our growth story and the value of our comprehensive biologics platform to the investment community. We are focused on execution and believe this collaboration will enhance our connection with current and prospective shareholders.' Xtant Medical has demonstrated strong business fundamentals, reporting fiscal year 2024 revenue of $117.5 million, a 29% year-over-year increase. The company has established significant market access through 450 integrated delivery network (IDN) contracts and a network of over 670 independent distributors, serving a $2.5 billion U.S. orthobiologics market within a $10.1 billion global spine market. About B2i Digital, Inc. B2i Digital, Inc. partners with investor conferences, public companies, and capital markets advisors through its Featured Conference, Featured Company, and Featured Expert programs. The firm leverages digital marketing technologies, a network of 1.3 million investors, and targeted introductions to connect key players in the markets. B2i Digital was founded in 2021 by David Shapiro, previously the Chief Marketing Officer and an investment banker at Maxim Group, LLC. David was also one of the founders of Maxim's investor awareness platform, B2i Digital Contact Information: David Shapiro Chief Executive Officer B2i Digital, Inc. 212.579.4844 Office [email protected] About Xtant Medical Holdings, Inc. Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. ( ) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers. Investor Contact Information: Kevin Gardner Managing Director LifeSci Advisors 646.889.1200 [email protected] View the original release on
Associated Press
33 minutes ago
- Associated Press
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
GEO-MVA received favorable European regulatory guidance supporting streamlined development pathway GEO-CM04S1 demonstrates superior robust immune responses in CLL patients; data presented at EHA 2025 Gedeptin(R) highlighted strong safety and efficacy for the treatment of solid tumors; data presented at AACR 2025 Company to host conference call today at 4:30 p.m. ET ATLANTA, GA - July 28, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies for infectious diseases and cancer, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. 'The second quarter marked a pivotal period for GeoVax, with compelling clinical data and regulatory milestones reinforcing the strength of our pipeline and our focus on accelerating to commercial status,' said David Dodd, GeoVax's Chairman and CEO. 'The favorable European regulatory guidance for GEO-MVA, robust immune responses demonstrated by GEO-CM04S1 in immunocompromised patients, particularly those with Chronic Lymphocytic Leukemia (CLL), and the continued progress towards initiation of the Gedeptin(R) Phase 2 trial highlight our expanding footprint in oncology and global infectious disease preparedness. These achievements reflect our commitment to advancing innovative, vaccines and immunotherapies that address urgent and underserved medical needs.' Clinical Trial Progress and Operational Developments GEO-MVA GEO-CM04S1 Gedeptin(R) Other Corporate Updates Second Quarter 2025 Financial Results Net Loss: Net loss for the three-month period ended June 30, 2025, was $5,369,783, or $0.35 per share, as compared to $5,064,042, or $1.99 per share, for the comparable period in 2024. For the six-month period ended June 30, 2025, the Company's net loss was $10,727,434, or $0.79 per share, as compared to $10,914,174, or $4.68 per share, in 2024. Revenue: During the three-month and six-month periods ending June 30, 2025, the Company reported $852,282 and $2,489,145 of government contract revenues associated with the BARDA/RRPV Project NextGen award, compared to $300,677 and $300,677 for the comparable periods in 2024. During the second quarter of 2025 GeoVax received notification that BARDA determined to terminate the contract for convenience to the government. R&D Expenses: Research and development expenses were $4,728,998 and $10,083,586 for the three-month and six-month periods ended June 30, 2025, compared with $4,276,868 and $8,702,596 for the comparable period in 2024, with the overall increase primarily due to program-specific costs associated with the BARDA/RRPV contract and GEO-MVA, partially offset by lower costs for the GEO-CM04S1 clinical trials and manufacturing costs not covered by the BARDA/RRPV contract. G&A Expenses: General and administrative expenses were $1,542,190 and $3,229,635 for the three-month and six-month periods ended June 30, 2025, compared to $1,086,030 and $2,543,383 for the comparable periods in 2024, with the overall increase primarily due to higher investor relations consulting costs and stock-based compensation expense. Cash Position: GeoVax reported cash balances of $3,093,862 at June 30, 2025, as compared to $5,506,941 at December 31, 2024. During July 2025, the Company completed a public offering of common stock and warrants with net proceeds of approximately $5.6 million. Summarized financial information is attached. Further information is included in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Conference Call Details Management will host a conference call and live audio webcast today, July 28, 2025, at 4:30 p.m. ET to review financial results and provide an update on corporate developments. A question-and-answer session will follow management's formal remarks. To access the live conference call, participants may register here. The live audio webcast of the call will be available under 'Events and Presentations' in the Investor Relations section of the GeoVax website at To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archive of the audio webcast will be available on GeoVax's website approximately two hours after the conference call and will remain available for at least 90 days following the event. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696 Media Contact: Jessica Starman [email protected] FINANCIAL TABLES FOLLOW View the original release on
